Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IDYA Stock Forecast 2025-2026
$33.64
Current Price
$2.95B
Market Cap
Buy 16
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to IDYA Price Targets
+134.8%
To High Target of $79.00
+36.7%
To Median Target of $46.00
-7.8%
To Low Target of $31.00
IDYA Price Momentum
-6.6%
1 Week Change
+5.1%
1 Month Change
+23.7%
1 Year Change
+30.9%
Year-to-Date Change
-9.3%
From 52W High of $37.08
+150.1%
From 52W Low of $13.45
📊 TOP ANALYST CALLS
Did IDYA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ideaya is one of their latest high-conviction picks.
Latest IDYA Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, IDYA has a bullish consensus with a median price target of $46.00 (ranging from $31.00 to $79.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $33.64, the median forecast implies a 36.7% upside. This outlook is supported by 16 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Anupam Rama at JP Morgan, projecting a 134.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IDYA Analyst Ratings
16
Buy
2
Hold
0
Sell
IDYA Price Target Range
Low
$31.00
Average
$46.00
High
$79.00
Current: $33.64
Latest IDYA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IDYA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 24, 2025 | Truist Securities | Gregory Renza | Buy | Initiates | $59.00 |
| Nov 11, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $46.00 |
| Oct 23, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $79.00 |
| Oct 21, 2025 | Goldman Sachs | Corinne Jenkins | Neutral | Maintains | $30.00 |
| Oct 21, 2025 | BTIG | Justin Zelin | Buy | Reiterates | $62.00 |
| Oct 21, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $41.00 |
| Sep 18, 2025 | Guggenheim | Paul Jeng | Buy | Initiates | $50.00 |
| Sep 12, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $44.00 |
| Sep 9, 2025 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $N/A |
| Sep 9, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $38.00 |
| Sep 9, 2025 | Stephens & Co. | Sudan Loganathan | Overweight | Reiterates | $45.00 |
| Sep 8, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Maintains | $45.00 |
| Sep 4, 2025 | Barclays | Peter Lawson | Overweight | Initiates | $40.00 |
| Sep 4, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Initiates | $41.00 |
| Sep 3, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $74.00 |
| Jul 28, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $72.00 |
| Jul 22, 2025 | TD Cowen | Tyler Van Buren | Buy | Initiates | $N/A |
| Jul 9, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $30.00 |
| Jun 26, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Initiates | $44.00 |
| May 22, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $66.00 |
Ideaya Biosciences Inc. (IDYA) Competitors
The following stocks are similar to Ideaya based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ideaya Biosciences Inc. (IDYA) Financial Data
Ideaya Biosciences Inc. has a market capitalization of $2.95B with a P/E ratio of -10.0x. The company generates $214.83M in trailing twelve-month revenue with a -74.8% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +52.2% and return on equity of -14.1%.
Valuation Metrics
Market Cap
$2.95B
Enterprise Value
$2.38B
P/E Ratio
-10.0x
PEG Ratio
0.0x
Price/Sales
13.9x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
+52.2%
Net Margin
-74.8%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+26.7%
Current Ratio
12.4x
Debt/Equity
2.5x
ROE
-14.1%
ROA
-10.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ideaya Biosciences Inc. (IDYA) Business Model
About Ideaya Biosciences Inc.
What They Do
Develops synthetic lethality-focused cancer therapies.
Business Model
The company integrates precision medicine with immuno-oncology to develop targeted cancer therapies. It generates revenue through the advancement of its therapeutic pipeline, which includes partnerships for research and development, addressing unmet medical needs in oncology.
Additional Information
Ideaya Biosciences is headquartered in South San Francisco, California, and focuses on innovative treatment options for patients with genetically defined cancers. The company targets key genetic mutations associated with various cancer forms, contributing significantly to the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
131
CEO
Mr. Yujiro S. Hata
Country
United States
IPO Year
N/A
Website
www.ideayabio.comIdeaya Biosciences Inc. (IDYA) Latest News & Analysis
Latest News
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
8 days ago
Quick Summary
IDEAYA Biosciences, Inc. (IDYA) presented at the Citi Annual Global Healthcare Conference 2025, providing insights into their developments and strategies.
Why It Matters
IDEAYA's presentation at a major healthcare conference signals potential insights into its pipeline and strategy, which can influence stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Biocytogen's partner, IDEAYA Biosciences, has received FDA clearance for a Phase 1 trial of IDE034, a bispecific ADC targeting B7H3/PTK7, marking a significant advancement in oncology.
Why It Matters
The FDA clearance for IDEAYA's IND application can boost Biocytogen's stock value and market confidence, signaling potential advancements in oncology and revenue opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
IDEAYA Biosciences (NASDAQ: IDYA) received FDA clearance for a Phase 1 trial of IDE034, a bispecific antibody-drug conjugate targeting B7H3 and PTK7 in solid tumors, with promising preclinical results.
Why It Matters
Clearance of the IND for IDE034 opens potential for significant market opportunity in oncology. Promising preclinical results suggest strong efficacy, impacting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IDEAYA Biosciences granted 17,600 non-qualified stock options to a new employee on November 26, 2025, as part of its compensation strategy.
Why It Matters
The grant of stock options to a new employee signals IDEAYA's commitment to growth and talent acquisition, potentially boosting its innovation and market position, influencing stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) will participate in upcoming investor relations events, focusing on its precision medicine oncology developments.
Why It Matters
IDEAYA's participation in investor events signals potential updates on drug development and strategic initiatives, influencing investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Ideaya Biosciences, Inc. has promising Phase 2 results for darovasertib in uveal melanoma, a $500M+ revenue potential, strong partnerships, and multiple near-term catalysts, indicating potential undervaluation at $3.1B.
Why It Matters
IDYA's promising Phase 2 results and strong partnerships indicate significant revenue potential, suggesting its $3.1B valuation may not reflect the full value of its oncology pipeline.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About IDYA Stock
What is Ideaya Biosciences Inc.'s (IDYA) stock forecast for 2026?
Based on our analysis of 26 Wall Street analysts, Ideaya Biosciences Inc. (IDYA) has a median price target of $46.00. The highest price target is $79.00 and the lowest is $31.00.
Is IDYA stock a good investment in 2026?
According to current analyst ratings, IDYA has 16 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $33.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IDYA stock?
Wall Street analysts predict IDYA stock could reach $46.00 in the next 12 months. This represents a 36.7% increase from the current price of $33.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ideaya Biosciences Inc.'s business model?
The company integrates precision medicine with immuno-oncology to develop targeted cancer therapies. It generates revenue through the advancement of its therapeutic pipeline, which includes partnerships for research and development, addressing unmet medical needs in oncology.
What is the highest forecasted price for IDYA Ideaya Biosciences Inc.?
The highest price target for IDYA is $79.00 from Anupam Rama at JP Morgan, which represents a 134.8% increase from the current price of $33.64.
What is the lowest forecasted price for IDYA Ideaya Biosciences Inc.?
The lowest price target for IDYA is $31.00 from at , which represents a -7.8% decrease from the current price of $33.64.
What is the overall IDYA consensus from analysts for Ideaya Biosciences Inc.?
The overall analyst consensus for IDYA is bullish. Out of 26 Wall Street analysts, 16 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $46.00.
How accurate are IDYA stock price projections?
Stock price projections, including those for Ideaya Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 11:58 AM UTC